

# STATE OF NEW YORK

10466

## IN SENATE

May 15, 2026

Introduced by Sen. BOTTCHER -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education

AN ACT to amend the education law and the public health law, in relation to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1 Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the  
2 education law, as amended by chapter 108 of the laws of 2025, is amended  
3 to read as follows:

4 b-1. Notwithstanding paragraph b of this [~~section~~] subdivision, the  
5 prescription label for mifepristone [~~ex~~], misoprostol, gonadotropin-re-  
6 leasing hormone agonists, pubertal suppressants, anabolic steroids,  
7 alpha reductase inhibitors, progestins, or drug classes for hormone  
8 replacement therapy for treatment of gender dysphoria, may include the  
9 name or address of the dispensing health care practice instead of the  
10 name of the dispenser.

11 § 2. Subdivision 1-a of section 6810 of the education law, as amended  
12 by chapter 108 of the laws of 2025, is amended to read as follows:

13 1-a. Notwithstanding subdivision one of this section, at the  
14 prescriber's request, the prescription label for mifepristone [~~ex~~],  
15 misoprostol, gonadotropin-releasing hormone agonists, pubertal suppres-  
16 sants, anabolic steroids, alpha reductase inhibitors, progestins, or  
17 drug classes for hormone replacement therapy for treatment of gender  
18 dysphoria, shall include the name or address of the prescribing health  
19 care practice instead of the name of the prescriber.

20 § 3. Section 280-d of the public health law, as added by chapter 108  
21 of the laws of 2025, is amended to read as follows:

22 § 280-d. Patient notification of prescription label change. A health  
23 care prescriber shall inform the patient if such prescriber has included  
24 or has requested to include the name or address of the prescribing  
25 health care practice instead of the name of such prescriber on the

EXPLANATION--Matter in italics (underscored) is new; matter in brackets  
[-] is old law to be omitted.

LBD10852-02-6

1 prescription label when prescribing mifepristone [~~or~~], misoprostol,  
2 gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic  
3 steroids, alpha reductase inhibitors, progestins, or drug classes for  
4 hormone replacement therapy for treatment of gender dysphoria.  
5 § 4. This act shall take effect immediately.